Skip to content

Randomized Controlled Trial Comparing Colorectal Adenoma Detection Rates Using LCI Combined with AI in Colonoscopy with Endocuff Vision vs. Transparent Hood

Randomized Controlled Trial Comparing Colorectal Adenoma Detection Rates Using LCI Combined with AI in Colonoscopy with Endocuff Vision vs. Transparent Hood - Endocuff vs. Transparent Hood in LCI/AI Colonoscopy for ADR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059880
Enrollment
780
Registered
2026-02-01
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with positive fecal occult blood tests, abdominal symptoms, or follow-up for colorectal polyps

Interventions

colonoscopy with an Endocuff Vision colonoscopy with a transparent hood

Sponsors

Saitama Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing colonoscopy after pre-procedural preparation 2. Age: 18 years or older 3. Gender: Not restricted 4. Positive fecal occult blood test, abdominal symptoms, or Surveillance for post-colonoscopic polypectomy 5. Patients who received verbal and written explanations of this study and provided written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients undergoing colonoscopy without prior bowel preparation 2. Patients with intestinal obstruction, stricture, fistula, post-colonic surgery, active inflammatory bowel disease, diverticulitis, active rectal bleeding, or where such conditions cannot be ruled out 3. Patients with alcoholism or drug dependence 4. Patients with severe hormonal disorders such as hyperthyroidism 5. Patients with severe cardiac, hepatic, renal dysfunction, or hematopoietic disorders 6. Patients with severe heart failure or respiratory failure 7. Pregnant women, lactating women, or patients who may be pregnant, or patients who wish to become pregnant during the study period. 8. Patients participating in other studies or clinical trials that may directly or indirectly influence the results of this study. 9. Patients suffering from life-threatening diseases. 10. Patients deemed unsuitable for inclusion by the principal investigator or sub-investigator.iratory failure (NYHA Class III or higher, Hughes-Jones Class IV or higher).

Design outcomes

Primary

MeasureTime frame
adenoma detection rate (ADR)

Countries

Japan

Contacts

Public ContactHiroyuki Imaeda

Saitama Medical University Hospital Department of Gastroenterology

imaedahi@yahoo.co.jp049-276-1829

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026